New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:47 EDTCARACara Therapeutics price target raised to $29 from $25 at Canaccord
Canaccord raised its price target on Cara Therapeutics to $29 from $25 on the CRS-45's potential in adjunct post-operative pain relief. The firm expects positive Phase 3 data in the second half of 2015 and could have potential US sales of $750M. Shares are Buy rated.
News For CARA From The Last 14 Days
Check below for free stories on CARA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 8, 2014
10:02 EDTCARACara Therapeutics price target raised to $30 from $23 at Piper Jaffray
Shares remain Overweight rated.
August 7, 2014
16:27 EDTCARACara Therapeutics reports Q2 EPS (16c), consensus (22c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use